Loading fund…
Loading fund…
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | ▲ +1.6% | ▲ +6.3% | ▲ +15.5% | ▲ +27.3% | ▲ +42.3% | ▲ +91.2% | ▲ +41.2% | ▲ +479.0% |
| Peer average | ▼ −1.0% | ▼ −4.0% | ▲ +1.7% | ▲ +13.4% | ▲ +9.3% | ▲ +90.3% | ▲ +37.9% | — |
| S&P 500 · VOO | ▼ −0.4% | ▲ +0.9% | ▲ +3.3% | ▲ +13.8% | ▲ +13.3% | ▲ +88.8% | ▲ +81.9% | — |
The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. This fund typically allocates a minimum of 90% of its total assets to the securities comprising the underlying index. The Index is constructed to achieve capital appreciation by thoroughly evaluating companies based on several investment criteria, including their price momentum, earnings growth, overall quality, management decisions, and valuation. It consists of 30 U.S.-based companies within the biotechnology and genome sectors. These companies are primarily involved in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, or they are businesses that stand to gain significantly from scientific and technological breakthroughs in biotechnology and genetic engineering. Both the ETF and its benchmark index undergo quarterly rebalancing and reconstitution in February, May, August, and November.
Distribution yield and SEC yield use different methodologies. Payouts may include income, capital gains, or return of capital.
| Ex-date | Pay date | Per share |
|---|---|---|
| 2026-09-21 | 2026-09-25 | $0.02 |
| 2026-06-22 | 2026-06-26 | $0.81 |
| 2026-03-23 | 2026-03-27 | $0.08 |
| 2025-12-22 | 2025-12-26 | $0.42 |
| 2025-09-22 | 2025-09-26 | $0.23 |
| 2025-06-23 | 2025-06-27 | $0.13 |
| 2025-03-24 | 2025-03-28 | $0.03 |
| 2024-06-24 | 2024-06-28 | $0.01 |
| 2024-03-18 | 2024-03-22 | $0.02 |
| 2023-06-20 | 2023-06-23 | $0.01 |
| 2020-03-23 | 2020-03-31 | $0.03 |
| 2018-09-24 | 2018-09-28 | $0.00 |
Estimated annual expense excludes trading costs and assumes constant assets. Fee waivers and fund costs can change.
Historical risk measures describe past behavior and do not predict future returns.
Hear the strategy from the people behind PBE.